Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology Spain Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific AntibodiesRelease Date:Quality Improvement Oncology All Enhancing HCP Education in Maternal VaccinationRelease Date:Education Vaccines Saudi Arabia Diagnosis and Treatment of Cancer CachexiaRelease Date:Education Oncology All Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic DiseasesRelease Date:Education Inflammation & Immunology USA B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology USA Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia AreataRelease Date:Education Inflammation & Immunology USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi ArabiaRelease Date:Research Vaccines Saudi Arabia Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing EquityRelease Date:Education Inflammation & Immunology Australia Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Pneumococcal Disease in TürkiyeRelease Date:Research Vaccines Turkey Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Pneumococcal Disease in TürkiyeRelease Date:Research Vaccines Turkey Title Grant Type Focus Area Country Application Due Date Innovative Digital Health Projects to increase the Quality of Life (QoL) of Multiple Myeloma (MM) patientsRelease Date:Quality Improvement Oncology Italy 2024 RD Global Monitoring anti-TFPI RESRelease Date:Research Rare Disease All Call for Independent Medical Education Grant Applications Oncology – Urothelial Carcinoma (UC)Education Oncology All Health Services Research to Improve Management of mBC Patients Treated with TucatinibRelease Date:Research Oncology All Addressing Multiple Myeloma Gaps in Care for Patients in Latin AmericaRelease Date:Partner: International Myeloma FoundationEducation Oncology Argentina, Brazil, Colombia, Mexico Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Management of Atopic Dermatitis / Alopecia AreataRelease Date:Education Inflammation & Immunology USA Improving the Care Process for Patients with Advanced Prostate CancerRelease Date:Partner: The American Urological Association Education and Research, Inc.; AstellasQuality Improvement Oncology USA Optimizing Care for patients with locally advanced or metastatic Urothelial Carcinoma (la/mUC)Release Date:Quality Improvement Oncology Canada Prospective Surveillance and Burden of Disease for RSV-Related Respiratory Tract Infections in Taiwanese Pediatric PopulationRelease Date:Research Vaccines Taiwan PARP-Inhibitor Combination Therapies: Personalized Treatment for Patients with Metastatic Castration-Resistant Prostate CancerRelease Date:Education Oncology Canada Developing Educational Initiatives for ALK+ Metastatic Non-small Cell Lung Cancer Tyrosine Kinase Inhibitors TherapyRelease Date:Education Oncology Canada